Current Treatment Options in Neurology

, Volume 15, Issue 2, pp 169–184

Limbic Encephalitis and Related Cortical Syndromes

  • Ignacio Rubio-Agusti
  • Miguel Salavert
  • Luis Bataller
PARANEOPLASTIC SYNDROMES (F GRAUS, SECTION EDITOR)

Opinion statement

Patients with limbic encephalitis and related cortical syndromes develop neurologic and psychiatric symptoms due to autoimmune damage of limbic and extralimbic brain areas. Some patients develop limbic encephalitis as a paraneoplastic manifestation of systemic cancer, where immune tolerance is thought to be lost. Serum and cerebrospinal antibodies against neuronal antigens can be detected in most patients. According to the type of antibodies found, patients may be classified into two broad groups, with implications for neurological and cancer diagnosis, treatment and prognosis. Patients with antibodies to intracellular neuronal antigens (onconeuronal antibodies: Hu, Ma2, amphiphysin, CV2/CRMP5) almost invariably have an underlying neoplasm (lung, testis, breast, etc.), often require aggressive combined antineoplastic and immunomodulatory treatment and their prognosis is usually poor. Patients with antibodies to cell-membrane antigens may present with classical limbic encephalitis (anti-LGI1 antibodies, other) or with a more diffuse stereotyped encephalitis, combining psychiatric symptoms, seizures, dyskinesias, catatonia and central hypoventilation (NMDAR-encephalitis). These patients may or may not have an associated tumor (thymoma, ovarian teratoma, etc.), are likely to improve with immunomodulatory treatment (and tumor removal for paraneoplastic cases) and have, overall, a better prognosis. Immunotherapy in patients with limbic encephalitis may be escalated according to the severity of neurological symptoms, the associated antibodies and the predicted success of antineoplastic treatment. First-line immunotherapies include high dose steroids, intravenous immunoglobulins and plasma exchange. Second-line drugs include Rituximab and Cyclophosphamide. For some patients, maintenance treatment with immunosuppressants might be required to prevent deterioration or relapses. Supportive treatment includes antiepileptic drugs, psychopharmacologic agents and scrutiny and prophylaxis of opportunistic infections.

Keywords

Limbic encephalitis Autoimmune encephalitis Antineuronal antibodies Onconeuronal antibodies Paraneoplastic neurologic disorders/syndromes Cortical syndromes Treatment 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003;78(11):1363–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol. 2008;10(3):131–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(Pt 3):701–12.PubMedGoogle Scholar
  6. 6.•
    Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776–85. Identification of the antigen in limbic encephalitis previously attributed to voltage-gated potassium channel antibodies.PubMedCrossRefGoogle Scholar
  7. 7.
    Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain. 1997;120(Pt 6):923–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007;78(4):381–5.PubMedCrossRefGoogle Scholar
  9. 9.•
    Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76(9):795–800. A study clarifying that most cases of paraneoplastic limbic encephalitis associated with small cell lung cancer previously thought to be seronegative have in fact antibodies against the GABA-B receptor.PubMedCrossRefGoogle Scholar
  10. 10.
    Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424–34.PubMedCrossRefGoogle Scholar
  11. 11.•
    Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77(18):1698–701. Identification of cell-membrane antibodies against mGluR5 in patients with paraneoplastic limbic encephalitis associated with Hodgkin disease.PubMedCrossRefGoogle Scholar
  12. 12.
    Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36.PubMedCrossRefGoogle Scholar
  13. 13.
    Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12):835–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54(7):899–904.PubMedCrossRefGoogle Scholar
  16. 16.
    Dalmau J, Bataller L. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am. 2006;20(6):1319–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Scheid R, Voltz R, Vetter T, Sabri O, von Cramon DY. Neurosyphilis and paraneoplastic limbic encephalitis: important differential diagnoses. J Neurol. 2005;252(9):1129–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol. 2001;50(5):612–9.PubMedCrossRefGoogle Scholar
  19. 19.••
    Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74. A thorough description of NMDAR-encephalitis, including epidemiological aspects, clinical features, diagnostic tests, response to treatment and outcome by the group that identified the antibodies and has the greatest experience with the condition.PubMedCrossRefGoogle Scholar
  20. 20.
    De Tiege X, Rozenberg F, Des Portes V, et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology. 2003;61(2):241–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-NMDAR encephalitis: clinical analysis and novel findings in a series of 20 patients. J Pediatr 2012. 10.1016/j.jpeds.2012.10.011
  22. 22.•
    Prüss H, Finke C, Höltje M, et al. NMDA receptor antibodies in herpes simplex encephalitis. 2012. 10.1002/ana.23689.Up to 30 % of patients with herpes simplex virus encephalitis may develop autoimmunity associated with NMDA receptor antibodies
  23. 23.
    Falip M, Carreno M, Miro J, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol. 2012;19(6):827–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Mata S, Muscas GC, Naldi I, et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol. 2008;199(1–2):155–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment. Semin Neurol. 2003;23(2):215–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19–e13.PubMedCrossRefGoogle Scholar
  27. 27.
    Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt 6):1138–48.PubMedCrossRefGoogle Scholar
  28. 28.
    Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6(1):55–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Shams’ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253(1):16–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Shavit YB, Graus F, Probst A, Rene R, Steck AJ. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol. 1999;45(2):255–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(Pt 8):1831–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Mathew RM, Vandenberghe R, Garcia-Merino A, et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology. 2007;68(12):900–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96–107.PubMedCrossRefGoogle Scholar
  35. 35.
    Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 1996;61(3):270–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Byrne TN, Isakoff SJ, Rincon SP, Gudewicz TM. Case records of the Massachusetts General Hospital. Case 27–2012. A 60-year-old woman with painful muscle spasms and hyperreflexia. N Engl J Med. 2012;367(9):851–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology. 2011;76(15):1355–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Iranzo A, Graus F, Clover L, et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol. 2006;59(1):178–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900.PubMedCrossRefGoogle Scholar
  40. 40.
    Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734–48.PubMedCrossRefGoogle Scholar
  41. 41.
    Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol. 2003;54(4):530–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004;62(7):1177–82.PubMedCrossRefGoogle Scholar
  43. 43.••
    Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470–8. A study of patients with limbic encephalitis identifying a subgroup characterized by predominant seizures and associated anti-GAD antibodies, often evolving into refractory epilepsy despite treatment, and comparing outcome with those with VGKC-antibodies (now LGI1-antibodies).PubMedCrossRefGoogle Scholar
  44. 44.
    Cash SS, Larvie M, Dalmau J. Case records of the Massachusetts General Hospital. Case 34–2011: A 75-year-old man with memory loss and partial seizures. N Engl J Med. 2011;365(19):1825–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69(2):303–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Becker EB, Zuliani L, Pettingill R, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2012;83(4):437–40.PubMedCrossRefGoogle Scholar
  47. 47.
    Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241–55.PubMedCrossRefGoogle Scholar
  48. 48.••
    Titulaer MJ, McCracken L, Gabilondo I, et al. Clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Neurology. 2012;78:PL01.001. This multicenter study with more than 500 patients and independent outcome assessment provides important information regarding outcome, risk of relapses and treatment strategy for NMDAR-encephalitis.CrossRefGoogle Scholar
  49. 49.
    Rubio-Agusti I, Dalmau J, Sevilla T, Burgal M, Beltran E, Bataller L. Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord. 2011;26(2):351–2.PubMedCrossRefGoogle Scholar
  50. 50.
    Gabilondo I, Saiz A, Galan L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;77(10):996–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11–8.PubMedCrossRefGoogle Scholar
  52. 52.•
    Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67–76. Identification of cell-membrane antibodies against GABA-B receptor in a subset of patients with limbic encephalitis with predominant seizures, amenable to improvement with immunotherapy.PubMedCrossRefGoogle Scholar
  53. 53.
    Kanter IC, Huttner HB, Staykov D, et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia. 2008;49(5):914–20.PubMedCrossRefGoogle Scholar
  54. 54.
    Liimatainen S, Peltola M, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2010;51(5):760–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Sadeghian H, Vernino S. Progress in the management of paraneoplastic neurological disorders. Ther Adv Neurol Disord. 2010;3(1):43–52.PubMedCrossRefGoogle Scholar
  56. 56.
    Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity. 2009;42(6):553–60.PubMedCrossRefGoogle Scholar
  57. 57.
    McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A. Immunomodulatory therapies in neurologic critical care. Neurocrit Care. 2010;12(1):132–43.PubMedCrossRefGoogle Scholar
  58. 58.
    Coret F, Bosca I, Fratalia L, Perez-Griera J, Pascual A, Casanova B. Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction. J Neurooncol. 2009;93(3):421–3.PubMedCrossRefGoogle Scholar
  59. 59.
    Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125(8):1747–54.PubMedCrossRefGoogle Scholar
  60. 60.
    Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15(1):e2–16.PubMedCrossRefGoogle Scholar
  61. 61.
    Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am. 2011;25(1):117–38.PubMedCrossRefGoogle Scholar
  62. 62.
    Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89(3):255–62.PubMedCrossRefGoogle Scholar
  63. 63.
    Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35–47.PubMedCrossRefGoogle Scholar
  64. 64.
    Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47(2):187–98.PubMedCrossRefGoogle Scholar
  65. 65.
    O'Neill BP, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol. 2007;9(3):364–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Cavallo R. The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy. Clin Microbiol Infect. 2011;17(12):1781–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–55.PubMedCrossRefGoogle Scholar
  69. 69.
    Kanner AM, Gidal BE. Pharmacodynamic and pharmacokinetic interactions of psychotropic drugs with antiepileptic drugs. Int Rev Neurobiol. 2008;83:397–416.PubMedCrossRefGoogle Scholar
  70. 70.
    Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry. 2011;168(3):245–51.PubMedCrossRefGoogle Scholar
  71. 71.
    Mann A, Machado NM, Liu N, Mazin AH, Silver K, Afzal KI. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis: a case and review of the literature. J Neuropsychiatry Clin Neurosci. 2012;24(2):247–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Ignacio Rubio-Agusti
    • 1
  • Miguel Salavert
    • 2
  • Luis Bataller
    • 1
  1. 1.Department of NeurologyHospital Universitari I Politècnic La FeValenciaSpain
  2. 2.Department of Infectious DiseasesHospital Universitari I Politècnic La FeValenciaSpain

Personalised recommendations